Related Experiment Video

Updated: Jul 4, 2026

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases
03:22

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases

Published on: March 1, 2024

[Pneumocystis jiroveci pneumonia during infliximab therapy]

Maria Eklund Josephson1, Lena Hagelskjaer Kristensen, Vibeke Charlotte Andersen

  • 1Regionshospitalet Viborg, Medicinsk Afdeling, Viborg.

Ugeskrift for Laeger
|June 21, 2008
PubMed

Insights

Tumor Necrosis Factor (TNF)-alpha inhibitors improve ulcerative colitis treatment but raise infection risks. Two patients developed Pneumocystis jiroveci pneumonia during infliximab therapy, successfully treated with sulfametoxazole/trimetroprim.

Area of Science:

  • Gastroenterology
  • Infectious Diseases
  • Pulmonology

Background:

  • Tumor Necrosis Factor (TNF)-alpha inhibitors have advanced ulcerative colitis (UC) management.
  • However, these biologics increase the risk of opportunistic infections.
  • Monitoring for infections is crucial during anti-TNF therapy.

Observation:

  • Two cases of Pneumocystis jiroveci pneumonia (PJP) occurred in patients with active UC.
  • Infliximab therapy was being administered to both patients.
  • Pulmonary symptoms and hypoxia were present.

Findings:

  • Pneumocystis jiroveci pneumonia was diagnosed during infliximab treatment for ulcerative colitis.
  • Both patients responded well to sulfametoxazole/trimetroprim treatment.
  • Prompt diagnosis and treatment are key.

Implications:

  • Increased awareness of PJP is necessary in UC patients on TNF-alpha inhibitors presenting with respiratory symptoms.
  • Early recognition and intervention can prevent severe outcomes.
  • This highlights the importance of vigilant monitoring for infections in immunosuppressed patients.

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...